WO2003070755A3 - Composes et compositions pour le transport de la cyclosporine a travers la barriere hemato-encephalique - Google Patents

Composes et compositions pour le transport de la cyclosporine a travers la barriere hemato-encephalique Download PDF

Info

Publication number
WO2003070755A3
WO2003070755A3 PCT/FR2003/000591 FR0300591W WO03070755A3 WO 2003070755 A3 WO2003070755 A3 WO 2003070755A3 FR 0300591 W FR0300591 W FR 0300591W WO 03070755 A3 WO03070755 A3 WO 03070755A3
Authority
WO
WIPO (PCT)
Prior art keywords
transporting
brain barrier
blood brain
compositions
compounds
Prior art date
Application number
PCT/FR2003/000591
Other languages
English (en)
Other versions
WO2003070755A2 (fr
Inventor
Patrick Mouchet
Anthony R Rees
Eskil Elmer
Marcus Floyd Keep
Original Assignee
Synt Em
Maas Biolab Llc
Patrick Mouchet
Anthony R Rees
Eskil Elmer
Marcus Floyd Keep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt Em, Maas Biolab Llc, Patrick Mouchet, Anthony R Rees, Eskil Elmer, Marcus Floyd Keep filed Critical Synt Em
Priority to AU2003229835A priority Critical patent/AU2003229835A1/en
Publication of WO2003070755A2 publication Critical patent/WO2003070755A2/fr
Publication of WO2003070755A3 publication Critical patent/WO2003070755A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La présente invention concerne un composé qui comprend au moins une molécule de cyclosporine et au moins un vecteur peptidique capable de transporter ladite molécule à travers la barrière hémato-encéphalique. L'invention concerne aussi l'utilisation dudit composé pour la préparation de compositions pharmaceutiques destinées notamment au traitement ou à la prévention de maladie du système nerveux central.
PCT/FR2003/000591 2002-02-22 2003-02-24 Composes et compositions pour le transport de la cyclosporine a travers la barriere hemato-encephalique WO2003070755A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003229835A AU2003229835A1 (en) 2002-02-22 2003-02-24 Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0202299A FR2836474B1 (fr) 2002-02-22 2002-02-22 Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
FR02/02299 2002-02-22

Publications (2)

Publication Number Publication Date
WO2003070755A2 WO2003070755A2 (fr) 2003-08-28
WO2003070755A3 true WO2003070755A3 (fr) 2004-03-04

Family

ID=27676020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000591 WO2003070755A2 (fr) 2002-02-22 2003-02-24 Composes et compositions pour le transport de la cyclosporine a travers la barriere hemato-encephalique

Country Status (3)

Country Link
AU (1) AU2003229835A1 (fr)
FR (1) FR2836474B1 (fr)
WO (1) WO2003070755A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2851471B1 (fr) * 2003-02-24 2006-07-28 Synt Em Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison
EP2269601A1 (fr) 2003-10-27 2011-01-05 City of Hope LR-9, LR-74 and LR-90 pour l'utilisation dans le traitement des complications résultant du diabète
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
EP1810675A1 (fr) * 2006-01-18 2007-07-25 Institut Curie Methode de traitement de la maladie de Huntington par l'inhibition de la dephosphorylation de la S421
WO2007094026A1 (fr) * 2006-02-17 2007-08-23 Paolo La Colla Traitement prophylactique et/ou thérapeutique de maladies prolifératives et conformationnelles
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
DE102008060549A1 (de) * 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
EP3149025B1 (fr) 2014-05-21 2019-06-26 Entrada Therapeutics, Inc. Peptides pénétrant dans les cellules et leurs procédés de fabrication et d'utilisation
WO2016033368A1 (fr) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Inhibiteurs améliorés de la peptidyl-calcineurine
WO2019148194A2 (fr) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Inhibiteurs peptidyliques de l'interaction calcineurine-nfat
WO2019165183A1 (fr) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions et méthodes de traitement de l'encéphalopathie mitochondriale neurogastro-intestinale
CN113952468B (zh) * 2021-09-26 2023-07-07 中国人民解放军空军军医大学 一种治疗心肌缺血再灌注损伤的环孢菌素a纳米药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001667A1 (fr) * 1990-07-25 1992-02-06 G.D. Searle & Co. Promedicaments nephroselectifs de regulation de l'activite du systeme nerveux sympathique du rein, utilises dans le traitement de l'hypertension
WO1999007728A2 (fr) * 1997-08-12 1999-02-18 Synt:Em (S.A.) Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2002067917A1 (fr) * 2001-02-23 2002-09-06 Cellgate, Inc. Compositions et procedes renforçant la livraison de medicaments dans et a travers tissus oculaires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001667A1 (fr) * 1990-07-25 1992-02-06 G.D. Searle & Co. Promedicaments nephroselectifs de regulation de l'activite du systeme nerveux sympathique du rein, utilises dans le traitement de l'hypertension
WO1999007728A2 (fr) * 1997-08-12 1999-02-18 Synt:Em (S.A.) Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2002067917A1 (fr) * 2001-02-23 2002-09-06 Cellgate, Inc. Compositions et procedes renforçant la livraison de medicaments dans et a travers tissus oculaires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C ROUSSELLE ET AL.: "New advances in the transport of doxoubicin through the blood-brain barrier by a peptide vector-mediated strategy", MOLECULAR PHARMACOLOGY, vol. 57, 2000, BALTIMORE, MD, US, pages 679 - 686, XP002226486, ISSN: 0026-895X *
J R ROTHBARD ET AL.: "Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation", NATURE MEDICINE., vol. 6, no. 11, November 2000 (2000-11-01), NATURE AMERICA, NEW YORK., US, pages 1253 - 1257, XP002226485, ISSN: 1078-8956 *
J TEMSAMANI ET AL.: "Brain drug delivery technologies: novel approaches for transporting therapeutics", PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY, vol. 3, no. 5, May 2000 (2000-05-01), ELSEVIER TRENDS JOURNALS, CAMBRIDGE,, GB, pages 155 - 162, XP002226487, ISSN: 1461-5347 *

Also Published As

Publication number Publication date
WO2003070755A2 (fr) 2003-08-28
AU2003229835A1 (en) 2003-09-09
FR2836474A1 (fr) 2003-08-29
FR2836474B1 (fr) 2004-12-24
AU2003229835A8 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2003070755A3 (fr) Composes et compositions pour le transport de la cyclosporine a travers la barriere hemato-encephalique
CA2427227A1 (fr) Compose de lactam
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
WO2005121097A3 (fr) Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
HK1048813A1 (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for their use.
WO2004026231A3 (fr) Preparation d'agents lipophiles
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
WO2006116148A3 (fr) Traitement de l'abus de substances toxiques
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004074232A8 (fr) Derives d'acide 1-phenylalcane-carboxylique pour le traitement de maladies neurodegeneratives
WO2007021886A3 (fr) Compositions de memapsine 2 tronquee et traitements associes
WO2003001983A3 (fr) Methodes de diagnostic et de traitement d'une maladie mediee par une fonction diminuee de mmp-2
WO2002094189A3 (fr) Compositions et procedes de traitement ou de prevention de convulsions ou de crises
CA2530613A1 (fr) Peptide derive de rasgap pour tuer selectivement des cellules cancereuses
MXPA03007635A (es) P-tienilbencilamidas que sirven como agonistas de receptores para angiotensina-(1-7), metodo para su produccion, su uso y preparaciones farmaceuticas que las contienen.
WO2003068147A3 (fr) Traitements de la neurotoxicite dans la maladie d'alzheimer
WO2007022042A3 (fr) Composes organiques
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2003037310A3 (fr) Inhibiteurs de transporteurs de medicament sous forme de proteines abc dans des cellules microbiennes
WO2003026700A3 (fr) Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
WO2001058470A3 (fr) Procedes permettant d'ameliorer la biodisponibilite d'un medicament
WO2004032975A3 (fr) Biphenyles et fluorenes comme agents d'imagerie pour la maladie d'alzheimer
WO2003066022A3 (fr) Preparation pharmaceutique stable pour le traitement des troubles gastro-intestinaux
WO2000061551A3 (fr) Ligands de recepteurs d'integrine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP